Loading stock data…
Xencor, Inc. (XNCR)
$19.44-0.09 (-0.46%)
Market ClosedLast close Jul 24
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Xencor, Inc. in the Healthcare sector is trading at $19.44 with a market capitalization of $1.1B. Wall Street consensus targets $28.33 (12 analysts), implying a +45.7% move over the next 12 months. The stock is currently near its 52-week high of $21.26, remaining 42.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +45.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.52M↓ | $28.24M↑ | $21.00M↓ | $43.61M↑ | $32.73M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$77.86M↓ | -$53.63M↓ | -$47.52M↓ | -$33.17M↑ | -$43.18M |
| Net Income | -$128.92M↓ | -$6.65M↓ | -$6.03M↑ | -$30.82M↑ | -$48.42M |
Peer Comparison
JNJUNHPFE
Fundamentals
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-33.44%
Volume
Today's trading volume
614,550
Recent News
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Sector Update: Healthcare Stocks Mixed Late Afternoon
Healthcare stocks were mixed late Friday afternoon, with the NYSE Healthcare Index unchanged and the
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone
By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clonal cell line generation. “Today’s news underscores our commitment to accelerate the development path of our growing BiTAC-TCE portfolio,” said Christoph Erkel, Ph.D., VERAXA’s Vice […] The post VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone appeared first on ExecE
Xencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets Caution
Xencor’s latest research update includes a US$1 increase in the stock’s price target, while the model’s fair value anchor of US$28.50 stays in place. Bullish analysts view this higher target as a sign that updated work still supports upside potential, even as more cautious voices highlight limited near term catalysts and execution risk around the pipeline. As you read on, you will see how to track these shifting views and what they might mean for your own Xencor watchlist. Stay updated as the...
These Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under Threat
Market forces rained on the parade of Xencor, Inc. ( NASDAQ:XNCR ) shareholders today, when the analysts downgraded...